Taken together, these data indicate that S109 might simultaneously perturb mediators of the critical pathways associated with glioma (the Foxo1, p53, and Rb1 signaling pathways) by promoting the nuclear retention of key tumor-suppressor proteins. This evidence concerns the gene RB1 and central nervous system cancer.